On January 7, 2026, Alumis Inc. announced the pricing of an upsized underwritten public offering of 17.65 million shares of common stock at $17.00 per share, yielding approximately $300.0 million in gross proceeds before underwriting discounts, commissions and expenses. The offering is expected to close on January 9, 2026, subject to customary conditions, and underwriters have a 30-day option to purchase an additional 2.65 million shares. Joint book-running managers for the transaction include Morgan Stanley, Leerink Partners, Cantor Fitzgerald and Wells Fargo Securities, with Baird and Oppenheimer serving as co-lead managers.

Alumis reported that envudeucitinib achieved statistically significant results across all primary and key secondary endpoints in two concurrent Phase III studies for moderate-to-severe plaque psoriasis. By Week 24, approximately two-thirds of patients attained a 90% reduction in Psoriasis Area and Severity Index (PASI 90), while over 40% achieved complete skin clearance (PASI 100). Safety data were consistent with previous studies, demonstrating a favorable tolerability profile with low rates of serious adverse events and no new safety signals.

Proceeds from the offering will be allocated to support the ongoing development of envudeucitinib, including the planned New Drug Application submission in mid-2026, and to advance the company’s broader pipeline of oral TYK2 inhibitors for systemic immune-mediated diseases. Additional funding will bolster clinical trials for A-005 in neuroinflammatory disorders and the subcutaneously delivered lonigutamab program in thyroid eye disease, as well as preclinical expansion driven by the proprietary data analytics platform.